tbuckley/cabot-search huggingface dataset:
Intratumoral heterogeneity on dedicated breast positron emission tomography before chemotherapy predicts the outcome of neoadjuvant chemotherapy in breast cancer
Authors: N. Masumoto, T. Kadoya, E. Suzuki, S. Sueoka, N. Goda, S. Sasada, A. Emi, R. Haruta, T. Kataoka, M. Okada
Journal: Annals of Oncology (2018)
P3.03-29 The Prognostic Effect of Tumor Mutation Burden and Smoking History in Resected EGFR Mutant Non-Small Cell Lung Cancer
Authors: H. Sorotsky, M. Cabanero, M. Moskovitz, J. Weiss, M. Pintilie, N. Leighl, P. Bradbury, G. Liu, A. Kia, T. Pugh, D. Torti, J. Torchia, M. Tsao, F. Shepherd
Journal: Journal of Thoracic Oncology (2018)
P1.13-17 Multicentre Phase II Trial of First-Line Afatinib in Patients with Suspected/Confirmed EGFR Mutant NSCLC: ctDNA and Long-Term Efficacy
Authors: S. Popat, A. Januszewski, L. Hughes, M. O'Brien, T. Ahmad, C. Lewanski, U. Dernedde, P. Jankowska, C. Mulatero, R. Shah, J. Hicks, T. Geldart, M. Cominos, G. Gray, J. Spicer, K. Bell, S. Roitt, K. Howarth, M. Cinelli, E. Green, C. Morris, Y. Ngai, A. Hackshaw
Journal: Journal of Thoracic Oncology (2018)
P2.13-30 High-Dose Icotinib in Advanced Non-Small Cell Lung Cancer with EGFR 21 L858R Mutation: The Randomized, Open-Label INCREASE Study
Authors: X. Li, L. Zhang, J. Da, Y. Wang, A. Zang, C. Ding, M. Zhao, W. Su, Y. Zhang, D. Zhong, J. Wu, G. An, C. Zhang, X. Hu, G. Cheng, H. Wang, Z. Han, X. He, J. Liu, L. Liang, S. Zhang
Journal: Journal of Thoracic Oncology (2018)
P2.17-21 Efficacy of Concurrent Carboplatin-Paclitaxel Chemoradiotherapy with 66 Gy for Elderly Patients with Stage III Non-Small Cell Lung Cancer
Authors: S. Miura, K. Inoue, S. Hontsu, H. Tanaka, M. Miyauchi, I. Asakawa, T. Tamamoto, M. Hasegawa
Journal: Journal of Thoracic Oncology (2018)
Abstract P101: Associations of Adiposity and Atrial Fibrillation in Older Adults: the Health ABC Study
Authors: Konstantinos N Aronis, Na Wang, Caroline Phillips, Emelia J Benjamin, Gregory M Marcus, Anne B Newman, Nicolas Rodondi, Suzanne Satterfield, Tamara B Harris, Jared W Magnani
Journal: Circulation (2015)

Introduction: Obesity is a well-recognized, modifiable risk factor for atrial fibrillation (AF). Limited studies have examined adiposity measures other than body mass index (BMI) and AF risk. We examined associations of adiposity measures with incident AF in a biracial cohort of older adults. Given the extensive racial differences between obesity and AF, we assessed for racial differences in relating adiposity and AF. Methods: The Dynamics of Health, Aging, and Body Composition Study is a prospective cohort of 3,075, community-dwelling, older adults. Adiposity measures were determined using anthropometry [BMI and abdominal circumference (AC)], CT [subcutaneous and visceral fat area (SAT, VAT)] and DXA (total and percent fat mass). AF was identified from the Center for Medicare and Medicaid Services. We determined the associations between adiposity measures and the 10-year risk of incident AF using Cox proportional hazards models. We examined for interactions between race and adiposity measures with the ou...
Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer
Authors: T. Yoshino, H. Iwata, K. Tamura, S. Takahashi, C. Redfern, S. Modi, T. Doi, H. Kawakami, H. Taniguchi, A. Takashima, K. Yamaguchi, J. Fisher, B. Li, K. Saito, Y. Fujisaki, M. Sugihara, J. Tsurutani
Journal: Annals of Oncology (2018)
Abstract 17129: Plasma-Derived Exosomes Regulate the Development of Hypertension in Rats
Authors: Kosuke Otani, Mai Yokoya, Muneyoshi Okada, Hideyuki Yamawaki
Journal: Circulation (2017)

Introduction: Exosomes are lipid bilayer-enclosed extracellular vesicles with 50-200 nm diameter. They contain not only cytoplasm-derived proteins, mRNAs and miRNAs but also plasma membrane-derived...
Histologic predictors of invasion in partially biopsied lentigo maligna melanoma
Authors: Iman Aouidad, Céline Fargeas, Pierre Romero, Jean-François Sei, Véronique Chaussade, Alain Beauchet, Thierry Clerici, Ute Zimmermann, Philippe Saiag, Elisa Funck-Brentano
Journal: Journal of the American Academy of Dermatology (2018)
Histamine and deep brain stimulation: the pharmacology of regularizing a brain
Authors: Timothy C. Whalen, Aryn H. Gittis
Journal: Journal of Clinical Investigation (2018)

Parkinson's disease (PD) patients have increased histamine in their basal ganglia, but the role of this neurotransmitter in PD is poorly understood. In this issue of the JCI, Zhuang et al. demonstrate that histamine levels rise in the subthalamic nucleus (STN) to compensate for abnormal firing patterns. Injection of histamine into the STN restores normal firing patterns and motor activity, whereas merely changing firing rates has no behavioral effect. Moreover, STN deep brain stimulation, a widespread therapy for PD, regularizes firing through endogenous histamine release. This suggests that abnormal firing patterns, rather than rates, cause PD symptoms, and this histaminergic pathway may lead to new treatments for the disease.
Abstract 18230: Wringing Pump or Roller Pump? Insights From Rotational Mechanics in Children With Left Ventricular Noncompaction Cardiomyopathy
Authors: Hythem Nawaytou, Putri Yubbu, Kelley Miller, Anirban Banerjee
Journal: Circulation (2015)

Introduction: Left ventricular noncompaction (LVNC) is a rare form of cardiomyopathy in children, characterized by abnormal endocardial myofiber arrangement. This may result in an altered pattern of LV rotation depicted by a “roller pump” like motion and described as rigid body rotation (RBR). This pattern, is characterized by the apex and the base rotating in the same direction. Hypothesis: To describe the LV rotational patterns in children with LVNC using speckle tracking echocardiography and detect the relationship between the different rotational patterns and measures of LV systolic function. Methods: We prospectively studied 19 children (age 0.9 to 17.8 years) with LVNC and compared them with age-matched controls. Apical and basal rotations, peak twist and peak torsion were analyzed as indices of systolic function. Peak apical recoil rate was measured as an index of diastolic function. Results: Children with LVNC had significantly lower apical rotation (6.26°± 3.09°, 8.59°± 2.19° p=0.01) than controls. In 7 out of 19 (36.8%) patients a pattern of RBR was detected. Twelve patients exhibited the typical “wringing” motion of the LV, where the apex rotated counterclockwise and the base clockwise. Patients with LVNC and RBR had significantly lower ejection fraction than patients with LVNC without RBR (49.1 ± 9.2% vs 60.3 ± 10.2%, p&lt;0.05). There were no significant differences in the remainder of the systolic and diastolic indices between LVNC patients and controls. Conclusions: Children with LVNC can exhibit an abnormal LV rotational pattern characterized by RBR that is associated with impaired systolic function.
Lipid management in patients with chronic kidney disease
Authors: Charles J. Ferro, Patrick B. Mark, Mehmet Kanbay, Pantelis Sarafidis, Gunnar H. Heine, Patrick Rossignol, Ziad A. Massy, Francesca Mallamaci, Jose M. Valdivielso, Jolanta Malyszko, Marianne C. Verhaar, Robert Ekart, Raymond Vanholder, Gerard London, Alberto Ortiz, Carmine Zoccali
Journal: Nature Reviews Nephrology (2018)
P1.04-28 Baseline Markers of Inflammation and Outcome with Nivolumab in Pretreated Non Small Cell Lung Cancers: A Retrospective Study
Authors: A. Russo, A. Battaglia, G. Provazza, G. Lo Certo, G. Ricciardi, M. Picciotto, A. Scimone, G. Toscano, V. Adamo, T. Franchina
Journal: Journal of Thoracic Oncology (2018)
Association between PD-L1 expression and survival in early stage non-small cell carcinoma
Authors: E. Gálvez, C. Gálvez Muñoz, A. Cotes Sanchís, A. Gonzaga López, M.M. Llorente Ostiategui, M. Montero Gómez, I. Aranda López, C. Llorca Ferrandiz
Journal: Annals of Oncology (2018)
Evaluation of practice patterns for prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) and antiemetic guidelines (GLs) adherence based on real-world prescribing data
Authors: M.S. Aapro, F. Scotté, Y. Escobar, L. Celio, R.D. Berman, A. Franceschetti, D. Bell, K. Jordan
Journal: Annals of Oncology (2018)
Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic ductal adenocarcinoma patients treated with FOLFIRINOX
Authors: A. Sehdev, O. Gbolahan, B.A. Hancock, M. Stanley, S. Shahda, J. Wan, H.H. Wu, M. Radovich, B. O’Neil
Journal: Annals of Oncology (2018)
MA18.07 Awareness of the Harms of Continued Smoking Among Lung Cancer (LC) Survivors
Authors: L. Eng, S. Liu, D. Farzanfar, D. Alton, E. Smith, A. Mccartney, S. Yeung, A. Basgaran, K. Balaratnam, K. Mattina, C. Harper, R. Mohan, M.C. Brown, A. Hope, P. Bradbury, A. Sacher, N. Leighl, F. Shepherd, A. Bezjak, D. Howell, J. Jones, W. Xu, D. Goldstein, W. Evans, P. Selby, M. Giuliani, G. Liu
Journal: Journal of Thoracic Oncology (2018)
P1.04-07 Pemetrexed Enhances Anti-Tumor Efficacy of PD-L1 blockade by Promoting Intra-Tumor Immune Response via Tumor and T Cell-Intrinsic Mechanisms
Authors: D. Schaer, S. Geeganage, N. Amaladas, Z.H. Lu, E. Rasmussen, A. Sonyi, D. Chin, A. Capen, Y. Li, C. Meyer, B. Jones, X. Huang, S. Luo, C. Carpenito, K. Roth, A. Nikolayev, B. Tan, M. Brahmachary, K. Chodavarapu, F. Dorsey, J. Manro, T. Doman, G. Donoho, G. Hall, M. Kalos, R. Novosiadly
Journal: Journal of Thoracic Oncology (2018)
P053 The Potential of Assessing Blood Tumor Mutation Burden (bTMB) Using a Large Panel
Authors: K. Zhang, Y. Tang, X. Xu, S. Zhang, W. Tao, Z. Rao, F. Wu, S. An, J. Liu, J. Yang, T. Hou, L. Zhang, Y. Zhang, L. Liu
Journal: Journal of Thoracic Oncology (2018)
Phase I study of KN035, a novel fusion Anti-PD-L1 antibody administered subcutaneously in patients with advanced solid tumors in the USA
Authors: K.P. Papadopoulos, W. Harb, N. Lu, X. Ma, Y. He, L. Yuan, M. Fu, Y. Lin, W. Xu, X. Wang, P. Wang, T. Xu, R. Dong, J. Gong
Journal: Annals of Oncology (2018)
Neutrophil-platelet score (NPS), a predictive systemic inflammation score for PD-1 immune checkpoint inhibitors (ICI) in pretreated advanced non-small cell lung cancer (NSCLC) patients
Authors: X. Mielgo Rubio, M. Sereno Moyano, L.E. Chara, R. López-Castro, J. Rubio-Martínez, A. Velastegui, C. Olier-Garate, S. Falagán, I. Gómez-Barreda, A. Riquelme, J. Silva-Ruiz, J. Moreno-Rubio, C. López, C. Bueno, A. Cardeña, E. Pérez-Fernández, M.P. Martí-Castelló, M.J. Sotelo-Lezama
Journal: Annals of Oncology (2018)
P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012
Authors: S. Antonia, S. Gettinger, H. Borghaei, J.W. Goldman, J. Brahmer, N. Ready, D. Gerber, L. Chow, R. Juergens, S. Laurie, F. Shepherd, X. Li, A. Li, W. Geese, M. Hellmann
Journal: Journal of Thoracic Oncology (2018)
Osteopontin protects against pneumococcal infection in a murine model of allergic airway inflammation
Authors: Gopinath Kasetty, Ravi K. V. Bhongir, Praveen Papareddy, Ellen Tufvesson, Henning Stenberg, Leif Bjermer, Anna Hultgårdh‐Nilsson, Heiko Herwald, Arne Egesten
Journal: Allergy (2018)

Abstract Background In atopic asthma, chronic Th2‐biased inflammation is associated with an increased risk of pneumococcal infection. The anionic phosphoglycoprotein osteopontin ( OPN ) is highly expressed in asthma and has been ascribed several roles during inflammation. This study aimed to investigate whether OPN affects inflammation and vulnerability to pneumococcal infection in atopic asthma. Methods House dust mite ( HDM ) extract was used to induce allergic airway inflammation in both wild‐type ( Spp1 +/+ ) and OPN knockout ( Spp1 −/− ) C57 BL /6J mice, and the airway was then infected with Streptococcus pneumoniae . Parameters reflecting inflammation, tissue injury, and bacterial burden were measured. In addition, samples from humans with allergic asthma were analyzed. Results Both allergen challenge in individuals with allergic asthma and the intranasal instillation of HDM in mice resulted in increased OPN levels in bronchoalveolar lavage fluid ( BALF ). More immune cells (including alveolar macrophages, neutrophils, eosinophils, and lymphocytes) and higher levels of proinflammatory cytokines were found in Spp1 −/− mice than in Spp1 +/+ mice. Moreover, OPN ‐deficient mice exhibited increased levels of markers reflecting tissue injury. Upon infection with S . pneumoniae, Spp1 +/+ mice with allergic airway inflammation had a significantly lower bacterial burden in both BALF and lung tissue than did Spp1 −/− mice. Furthermore, Spp1 −/− mice had higher levels of cytokines and immune cells in BALF than did Spp1 +/+ mice. Conclusion OPN reduces inflammation, decreases tissue injury, and reduces bacterial loads during concurrent pneumococcal infection and allergic airway inflammation in a murine model. These findings suggest that OPN significantly affects vulnerability to pneumococcal infection in atopic asthma.
P3.01-64 Preliminary Data of Diverse Therapies in Patients with Advanced Non–Small-Cell Lung Cancer Harbouring RET-Rearrangement
Authors: C. Lu, H. Tu, H. Yan, X. Zhang, B. Wang, Z. Wang, A. Li, J. Lin, Y. Li, E. Ke, J. Song, S. Chen, Y. Wang, Y. Guan, X. Xia, X. Yi, Y. Wu, J.-. Yang
Journal: Journal of Thoracic Oncology (2018)
Expanding Therapeutic Opportunities for Hematopoietic Stem Cell Transplantation: T Cell Depletion as a Model for the Targeted Allograft
Authors: Christina Cho, Miguel-Angel Perales
Journal: Annual Review of Medicine (2018)

Allogeneic hematopoietic cell transplantation is a fundamental part of the treatment of hematologic malignancies and marrow failure syndromes, but complications including graft-versus-host disease, prolonged immune deficiency and infection, and organ toxicities, as well as relapse, remain obstacles to improved overall survival. As the cellular characteristics of the allograft can exert significant impact on outcomes, the development of more strategically designed grafts represents a rich area for therapeutic intervention. We describe the use of ex vivo T cell-depleted grafts as a model for the targeted graft and review evolving knowledge and approaches for further refinement of allografts to improve patient outcomes.
P1.16-32 Lung Cancer Completeness of Resection in Uniportal Versus Multiportal Video-Assisted Thoracoscopic Surgery Lobectomy
Authors: E. Bourdages-Pageau, R. Alves, A. Vieira, C. Paradis-Garneau, Y. Lacasse, P. Ugalde
Journal: Journal of Thoracic Oncology (2018)
P1.01-40 Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly pts with Untreated Advanced NSCLC: TORG1323
Authors: K. Ito, O. Hataji, S. Tanzawa, T. Harada, N. Fujimoto, A. Bessho, K. Takamura, K. Takahashi, T. Shinkai, T. Kozuki, M. Satouchi, T. Kato, N. Seki, T. Shukuya, N. Yamashita
Journal: Journal of Thoracic Oncology (2018)
Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies
Authors: G. Bianchini, J. Parker, L. Carey, C.M. Perou, L. Sica, A. Prat, T. Pieńkowski, Y.-H. Im, G.V. Bianchi, T. Ling-Ming, M.-C. Liu, A. Lluch, V. Semiglazov, J. de la Haba-Rodriguez, D.-Y. Oh, B. Poirier, J.L. Pedrini, P. Valagussa, L. Gianni
Journal: Annals of Oncology (2018)
Efficacy and toxicity of endocrine therapy + cyclin-dependent kinases 4/6 inhibitors (iCDK4/6) in metastatic breast cancer patients according to gBRCA status
Authors: L.I. Bruno, M.V. Costanzo, C.A. Ostinelli, A.A. Nervo, J. Nadal, F. Colo, J. Loza, C.M. Loza, C. Ponce, V. Fabiano, A.G. Blanco, C. Perez de la Puente, R.D. Chacon
Journal: Annals of Oncology (2018)
Immune related adverse events across cancer types: Incidence, risk factors and survival
Authors: D.H. Owen, J. Burkart, S. Patel, L. Wei, G. Tinoco, D. Liebner, K. He, P.G. Shields, E.M. Bertino, C.J. Presley, A. Johns, E. Folefac, T. Olencki, D.P. Carbone, C. Verschraegen, G.A. Otterson, K.L. Kendra
Journal: Annals of Oncology (2018)
Hypothyroidism is associated with improved survival prognosis in patients with newly diagnosed brain metastases
Authors: C. Wippel, A.M. Starzer, A.S.S. Berghoff, E. Bergen, P. Wolf, G. Widhalm, J.M. Frischer, B. Gatterbauer, C. Marosi, K. Dieckmann, R. Bartsch, M. Preusser
Journal: Annals of Oncology (2018)
P1.04-19 Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Predict Survival After Immunotherapy in Non-Small Cell Lung Cancer
Authors: M. Oh, D. Saravia, S. Agte, A. Rahbari, W. Park, G. Lopes, Y. Chae
Journal: Journal of Thoracic Oncology (2018)
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)
Authors: M. Kundranda, A.C. Gracian, S.F. Zafar, E. Meiri, J. Bendell, H. Algül, F. Rivera, E.R. Ahn, D. Watkins, U. Pelzer, V. Charu, A. Zalutskaya, G. Kuesters, J.M. Pipas, S. Santillana, V. Askoxylakis, A.H. Ko
Journal: Annals of Oncology (2020)
P2.03-07 Radiomic Signatures Linked to Genetic Alterations as Detected by Next-Generation Sequencing: A Radiogenomics Analysis of Early-Stage NSCLC
Authors: S. Tian, E. Schreibmann, S. Goyal, M. Rupji, R. Cassidy, C. Escott, M. Ferris, P. Patel, W. Curran, K. Higgins
Journal: Journal of Thoracic Oncology (2018)
P1.02-03 The Role of Lung Cancer Advocacy Organizations in Biomarker Testing
Authors: W. Boerckel, C. Aldige, U. Roy, A. Ciupek, D. Donaldson, H. Grossman, C. Langhorne, L. Rosenthal, C. Saxton, G. Silvestri, R. Smith, L. Wenger
Journal: Journal of Thoracic Oncology (2018)
TRIANgLE study (JCOG1510): A phase III study of tri-modality combination therapy with induction docetaxel (DOC), cisplatin (CDDP), 5-fluorouracil (FU) (DCF) vs definitive chemoradiotherapy (dCRT) for locally advanced unresectable squamous cell carcinoma (SCC) of the thoracic esophagus
Authors: H. Daiko, H. Hara, H. Ogawa, K. Hori, J. Mizusawa, S. Ozawa, M. Takagi, M. Tanaka, H. Baba, Y. Shirakawa, M. Tsuda, S. Nakagawa, H. Takeuchi, T. Abe, Y. Ito, T. Kojima, T. Kadota, H. Fukuda, K. Kato, Y. Kitagawa
Journal: Annals of Oncology (2018)
P3.01-104 EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report
Authors: W. Wang, C. Xu, W. Zhuang, Z. Song, Y. Huang, Y. Chen, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sézary syndrome
Authors: H Torrey, M Khodadoust, L Tran, D Baum, A Defusco, Y H Kim, D L Faustman
Journal: Leukemia (2018)

Sézary syndrome (SS) is a rare form of cutaneous T-cell lymphoma often refractory to treatment. SS is defined as adenopathy, erythroderma with high numbers of atypical T cells. This offers an opportunity for new interventions and perhaps antibody-based therapeutic by virtue of its high expression of the TNFR2 oncogene on the tumor cells and on T-regulatory cells (Tregs). Potent human-directed TNFR2 antagonistic antibodies have been created that preferentially target the TNFR2 oncogene and tumor-infiltrating TNFR2+ Tregs. Here we test the therapeutic potential of TNFR2 antagonists on freshly isolated lymphocytes from patients with Stage IVA SS and from healthy controls. SS patients were on a variety of end-stage multi-drug therapies. Baseline burden Treg/T effector (Teff) ratios and the responsiveness of tumor and infiltrating Tregs to TNFR2 antibody killing was studied. We show dose-escalating concentrations of a dominant TNFR2 antagonistic antibody killed TNFR2+ SS tumor cells and thus restored CD26− subpopulations of lymphocyte cell numbers to normal. The abundant TNFR2+ Tregs of SS subjects are also killed with TNFR2 antagonism. Beneficial and rapid expansion of Teff was observed. The combination of Treg inhibition and Teff expansion brought the high Treg/Teff ratio to normal. Our findings suggest a marked responsiveness of SS tumor cells and Tregs, to targeting with TNFR2 antagonistic antibodies. These results show TNFR2 antibodies are potent and efficacious in vitro.
A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors
Authors: C.S. Denlinger, J.R. Infante, R. Aljumaily, A. Naing, A. Chintakuntlawar, N.A. Rizvi, H. Ross, M. Gordon, R. Kumar, M. Ma, L. Yan, P. Vicini, N. Standifer, J. Cann, A. Perera, N. Durham, S. Krishnan, A. Balmanoukian
Journal: Annals of Oncology (2018)
MA24.06 Long Non-Coding Rna Expression Patterns Delineate Infiltrating Immune Cells in the Lung Tumour Microenvironment
Authors: A. Sage, K. Ng, E. Marshall, K. Enfield, G. Stewart, S. Martin, B. Minatel, C. Brown, N. Abraham, W. Lam
Journal: Journal of Thoracic Oncology (2018)
MA25.11 Clinical and Molecular Predictors of Outcome in Patients with EGFR mutant NSCLC Brain Metastases treated with RT
Authors: F. Moraes, J. Weiss, M. Moskovitz, H. Sorotsky, M. Pintilie, N. Leighl, P. Bradbury, G. Liu, G. Zadeh, M. Doherty, A. Kia, J. So, M. Cabanero, T. Pugh, V. Sugumar, D. Torti, M. Tsao, J. Torchia, D. Shultz, F. Shepherd, B. Lok
Journal: Journal of Thoracic Oncology (2018)
P1.01-70 Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel + Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+)
Authors: D. Morgensztern, R. Govindan, M. Cobo, S. Ponce Aix, P.E. Postmus, C. Lewanski, J. Bennouna, J. Fischer, O. Juan-Vidal, D. Stewart, A. Ardizzoni, R. Bhore, M. Wolfsteiner, M. Reck, D. Talbot, T.J. Ong
Journal: Journal of Thoracic Oncology (2018)
Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET
Authors: Franziska J. Vettermann, Jörg Felsberg, Guido Reifenberger, Martin Hasselblatt, Robert Forbrig, Georg Berding, Christian la Fougère, Norbert Galldiks, Jens Schittenhelm, Joachim Weis, Nathalie L. Albert, Ulrich Schüller
Journal: Clinical Nuclear Medicine (2018)

Background Recent data suggest that diffuse gliomas carrying mutations in codon 34 of the H3 histone family 3A protein represent a very rare, distinct subgroup of IDH–wild type malignant astrocytic gliomas. However, characteristics detectable by MRI and 18 F-FET PET in H3-G34-mutant gliomas are unknown. Methods We report on MRI and 18 F-FET PET findings in 8 patients from 4 German centers with H3-G34-mutant diffuse gliomas. MRI analyses included multifocality, contrast enhancement, necrosis, cysts, hemorrhages, calcification, and edema. 18 F-FET PET characteristics were evaluated on the basis of static 18 F-FET PET parameters, such as maximal tumor-to-background ratio (TBR max ) and biological tumor volume (BTV), as well as the minimal time-to-peak (TTP min ) obtained from dynamic 18 F-FET PET data. Results MRI showed multifocal lesions in 2 of 8, contrast enhancement in 6 of 8, necrosis in 3 of 8, cysts in 3 of 8, hemorrhage in 1 of 8, and calcifications in 1 of 8 patients. None of the tumors showed marked peritumoral edema. However, all 8 H3-G34-mutant gliomas were characterized by a high uptake intensity on 18 F-FET PET with a median TBR max of 3.4 (range, 2.5–11.7) and a relatively diffuse uptake pattern leading to a large BTV (median, 41.9 mL; range, 7.5–115.6). Dynamic PET data revealed a short median TTP min of 12.5 minutes. Conclusions MRI features of diffuse gliomas with H3-G34 mutation may present very heterogeneously with some cases not even fulfilling the imaging criteria of high-grade glioma. In contrast, in 18 F-FET PET, these tumors show an extensive and diffuse tracer uptake resulting in large BTV with a high TBR max and a short TTP min , thus resembling PET characteristics of aggressive high-grade gliomas, namely, glioblastomas.
The role of modulation of somatostatin analogues (SSAs) in association to peptide receptor radionuclide therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) entero-pancreatic neuroendocrine tumours (EP-NETs)
Authors: N. Prinzi, E. Seregni, A. Raimondi, M. Maccauro, F. Corti, G. Lo Russo, F. Nichetti, M. Torchio, J. Coppa, G. Peverelli, F. Pagani, M. Di Bartolomeo, V. Mazzaferro, F. de Braud, S. Pusceddu
Journal: Annals of Oncology (2018)